NVCR250117P35000
- 7.45
- +2.65+55.21%
Novocure Newsroom
Evercore Maintains Novocure(NVCR.US) With Buy Rating, Raises Target Price to $46
NovoCure Analyst Ratings
Piper Sandler Maintains Overweight on NovoCure, Raises Price Target to $42
Piper Sandler Maintains Novocure(NVCR.US) With Buy Rating, Raises Target Price to $42
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF) and NovoCure (NVCR)
A Quick Look at Today's Ratings for Novocure(NVCR.US), With a Forecast Between $30 to $40
Novocure Is Maintained at Buy by HC Wainwright & Co.
Positive Outlook for NovoCure: Buy Rating Backed by Successful PANOVA-3 Trial and Promising Market Potential
HC Wainwright & Co. Reiterates Buy on NovoCure, Raises Price Target to $38
Leerink Partners Adjusts NovoCure Price Target to $33 From $28, Maintains Outperform Rating
Evercore ISI Group Upgrades NovoCure to Outperform, Raises Price Target to $30
Evercore Upgrades Novocure(NVCR.US) to Buy Rating, Raises Target Price to $30
NovoCure Analyst Ratings
NovoCure's Buy Rating Backed by FDA Approval and Strategic Growth Plans Amidst Potential Risks
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $30
Analysts Conflicted on These Healthcare Names: Penumbra (PEN), Kymera Therapeutics (KYMR) and NovoCure (NVCR)
NovoCure Analyst Ratings
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $30
Piper Sandler Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $28
Piper Sandler Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $28